BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.
The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.
BioLineRx Ltd. agreed to sell 80% of future APHEXDA royalty payments attributable to sales on or after closing to SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, for a $5.6 million one-time purchase price at closing, less the purchaser’s documented reasonable transaction expenses capped at $100,000. The sold portion corresponds to a 14.4% royalty on net sales. BioLineRx will retain the remaining 20%, corresponding to a 3.6% royalty, as well as royalties for pre-closing periods and potential future commercial milestone payments. Closing is expected on or about November 30, 2026, subject to customary conditions and Ayrmid’s consent.
At closing, BioLineRx will make a $3.0 million partial loan prepayment to Kreos Capital VII Aggregator SCSp. Approximately $2.0 million will then remain outstanding under a new repayment schedule, and the $4.0 million minimum cash balance covenant will be eliminated. Chardan Capital Markets is due an approximately $0.4 million advisory fee at closing. If completed, BioLineRx intends to use net proceeds for research and development, including GLIX1, working capital and general corporate purposes. GLIX1’s Phase 1/2a trial is enrolling its fourth of five planned dosing cohorts.
BioLineRx Ltd. (BLRX) is the issuer in a Schedule 13G in which Armistice Capital, LLC and its managing member Steven Boyd each report beneficial ownership of 514,365 American Depositary Shares (ADSs), or 9.99% of the class. Each reports shared voting and dispositive power over 514,365 ADSs; each ADS represents 600 ordinary shares. Armistice Capital Master Fund Ltd. is the direct holder. Armistice Capital is the Fund’s investment manager, and Boyd may be deemed to beneficially own the securities through his role as managing member. The Master Fund has the right to receive dividends and sale proceeds and disclaims beneficial ownership because it cannot vote or dispose of the securities under its Investment Management Agreement.
BioLineRx Ltd. (BLRX) and Hemispherian AS reported two GLIX1 posters presented at the 31st Society for Neuro-Oncology Annual Meeting, covering an ongoing Phase 1/2a study and preclinical work.
Dosing has begun in the study’s fourth cohort, and no significant treatment-emergent adverse events have been observed. Remaining cohorts will include patients in a window-of-opportunity setting to assess GLIX1 penetration and biological activity in human tumor tissue.
In models, GLIX1 eradicated tumors and prolonged survival in SNB19 CDX, inhibited tumor growth dose-dependently in U87MG CDX, and inhibited growth in TMZ-resistant BN2276 PDX, where TMZ was not effective. In the U87MG model, GLIX1 was detected in the brain at all tested doses; total exposure increased at higher doses, and tumor 5hmC increased dose-dependently and correlated with growth inhibition.
BioLineRx Ltd. and Hemispherian AS presented preclinical data showing GLIX1 combined with olaparib, veliparib and niraparib produced reproducible synergy across HR-proficient ovarian cancer cell lines, with ZIP synergy scores from 10.9 to 43.2. In a 28-day HR-proficient ovarian cancer patient-derived xenograft study, GLIX1 at 50 mg/kg daily plus olaparib at 10 mg/kg daily produced statistically significant tumor growth inhibition versus vehicle control; activity was comparable to cisplatin and greater than either agent alone at its respective optimal dose.
The monotherapy comparison used GLIX1 at 250 mg/kg daily and olaparib at 50 mg/kg daily. GLIX1 tumor-to-plasma concentration ratios were approximately 50%. BioLineRx said GLIX1 is being evaluated in a Phase 1/2a glioblastoma trial, with plans to include an ovarian cancer arm in the expansion phase.
BioLineRx Ltd. registered for resale up to 2,023,382 ADSs issuable upon exercise of warrants held by Armistice Capital, LLC. Each ADS represents 600 ordinary shares, or up to 1,214,029,200 ordinary shares. The selling shareholder may sell all, some or none through market, negotiated or other transactions.
BioLineRx receives no proceeds from ADS resales; it may receive proceeds if warrants are exercised for cash. Full cash exercise of all warrants would produce $5.6 million; the warrants also may be exercised cashlessly in certain circumstances. Their exercise price is $2.78 per ADS, with a five-year term from issuance and an ownership limit of 4.99%, or 9.99% at the holder’s election. BioLineRx will pay estimated registration expenses of $30,000. The 2025 audit report incorporated by reference contains an explanatory paragraph related to BioLineRx’s ability to continue as a going concern.
BioLineRx Ltd. filed to register for resale up to 2,023,382 ADSs, each representing 600 ordinary shares, issuable upon exercise of warrants held by Armistice Capital, LLC. The selling shareholder may not sell until the registration statement becomes effective. The ADSs represent up to 1,214,029,200 ordinary shares; BioLineRx reported 2,986,929,790 ordinary shares outstanding as of September 24, 2026.
BioLineRx receives no proceeds from resales. It may receive proceeds only if the warrants are exercised for cash; full cash exercise would produce $5.6 million, intended for research and development, working capital and general corporate purposes. The warrants have a $2.78 per ADS exercise price, may be exercised cashlessly in certain circumstances, and have a 4.99% beneficial-ownership limit, or 9.99% at the holder’s election. BioLineRx states that resales could adversely affect the ADS market price. Its incorporated 2025 financial statements include an auditor’s explanatory paragraph concerning its ability to continue as a going concern.
BioLineRx Ltd. (BLRX) said shareholders approved, by the requisite majority under the Israel Companies Law and the company’s articles of association, each proposal set forth in the proxy statement for its September 23, 2026 annual general meeting. The report is incorporated by reference into all effective registration statements BioLineRx filed under the Securities Act of 1933.
BioLineRx Ltd. (BLRX) reports that two scientific abstracts on its lead asset GLIX1, developed with Hemispherian AS, have been accepted for presentation at the EANO 2026 neuro-oncology conference, including a mini-oral highlighting preclinical efficacy in orthotopic glioblastoma models and an e-poster detailing the ongoing Phase 1/2a trial design.
Preclinical data show that GLIX1, an oral TET2 activator targeting the DNA damage response, achieved brain exposure at 68–85% of plasma levels in mice and produced dose-dependent tumor growth inhibition and survival benefit across two orthotopic GBM xenograft models at all tested doses. These findings supported initiation of a first-in-human, open-label, multicenter Phase 1/2a study in recurrent or progressive high-grade glioma using a BOIN dose-escalation design across up to 5 dose levels in up to 30 patients, with primary endpoints focused on safety, tolerability, and determination of MTD/RP2D.
BioLineRx Ltd. (BLRX), an Israel-incorporated biotechnology company, filed a Form D for an exempt offering under Rule 506(b) of Regulation D. The notice covers a completed $3,750,000 offering of options/warrants and the securities issuable upon their exercise, with no remaining amount to be sold.
The securities were issued together with a registered direct offering of 480,696 American depositary shares (ADSs) and 868,225 pre-funded warrants, plus unregistered warrants to purchase 2,023,382 ADSs. BioLineRx intends to use the net proceeds for research and development activities, working capital, and general corporate purposes. Chardan Capital Markets LLC is entitled to a 1.0% management fee on gross proceeds and $50,000 for accountable expenses, with no sales commissions or finder’s fees reported.